$599

Ph2 ARO-INHBE MASH Study; Arrowhead Plozasiran for sHTG in STAR Program; ZUPREME-2 Topline Data; Zealand New SVP BD; Esperion and Renata Generic BA Agreement; Ozari Offers Compounded Tirzepatide

A series of cardiometabolic-related news items has been observed from Arrowhead Pharmaceuticals, Zealand Pharma, Esperion, and Ozari Health. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here